therapeutic peptide development

Allysta Pharmaceuticals is a private venture-backed clinical stage biopharmaceutical focused on rare diseases with high unmet needs. It develops first-in-class therapeutic peptides with anti-fibrotic, anti-inflammatory, cell regenerative, and metabolic effects. Its lead drug ALY688ER is an extended release formulation and potent activator of adiponectin signaling pathways; ALY688 is described as the first adiponectin receptor agonist to enter human testing. Lead indication is Duchenne muscular dystrophy.

Read more

clinical-stage biopharmaceutical researchdrug development